Drug Trial Radar · NCT00391872
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome
Last checked: Nov 20, 2026Latest source record: Mar 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18,624
Actual
Start
Oct 2006
Primary completion
Mar 2009
Study completion Mar 2009
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 25, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.
Conditions
- Acute Coronary Syndrome
Interventions
TicagrelorDrug
Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
ClopidogrelDrug
Clopidogrel 75 mg once daily dose (ODD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and StrokeTime frame: Randomization up to 12 months
- Participants With Any Major Bleeding EventTime frame: First dosing up to 12 months
Locations
672 sites in 44 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
Research Site
Mobile, Alabama
Research Site
Tucson, Arizona
Research Site
Bakersfield, California
Research Site
Beverly Hills, California
Research Site
Burbank, California
Research Site
Healdsburg, California
Research Site
Los Angeles, California
Research Site
Roseville, California
Research Site
Sacramento, California
Research Site
San Diego, California
Research Site
Torrance, California
Research Site
Fort Collins, Colorado
Research Site
Danbury, Connecticut
Research Site
Hartford, Connecticut
Research Site
Newark, Delaware
Research Site
Washington D.C., District of Columbia
Research Site
Atlantis, Florida
Research Site
Daytona Beach, Florida
Research Site
Fort Lauderdale, Florida
Research Site
Hollywood, Florida
Research Site
Jacksonville, Florida
Research Site
Jupiter, Florida
Research Site
Melbourne, Florida
Research Site
Miami Beach, Florida
Research Site
Ocala, Florida
Research Site
Orlando, Florida
Research Site
Ormond Beach, Florida
Research Site
Pensacola, Florida
Research Site
Sarasota, Florida
Research Site
St. Petersburg, Florida
Research Site
Chicago, Illinois
Research Site
Park Ridge, Illinois
Research Site
Rock Island, Illinois
Research Site
Rockford, Illinois
Research Site
Indianapolis, Indiana
Research Site
Muncie, Indiana
Research Site
Valparaiso, Indiana
Research Site
Iowa City, Iowa
Showing 40 of 672 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.